Circulating Tumor Dna

In this video, Angela DeMichele, MD, MSCE, co-leader of the Breast Cancer Research Program and director of the Breast Cancer Clinical Trials Unit at Penn Medicine, spoke with Healio about circulating tumor DNA in breast cancer.

Circulating tumor DNA can be readily detected in patients with central nervous system lymphoma and may be a strong clinical biomarker for risk stratification, outcomes prediction and surgery-free lymphoma classification, results showed.

Reduction in circulating tumor DNA appeared correlated with longer OS among patients with previously treated metastatic uveal melanoma who received tebentafusp, according to study results presented at the virtual ESMO Congress.

Patients with diffuse large B-cell lymphoma who achieved a durable response to axicabtagene ciloleucel showed evidence of lower circulating tumor DNA levels before and after treatment, according to results of a prospective study.

Evaluation of multiple classifiers, both alone and in combination, supports the decision to focus on cell-free DNA methylation patterns to detect cancer and predict the cancer signal origin, according to a presentation at ESMO Congress 2021.

Scientists have made amazing advances in recent years in understanding the molecular biology of cancer.

Using circulating tumor DNA to predict relapse after autologous stem cell transplantation in patients with multiple myeloma showed feasibility in a study presented at the virtual ASCO Annual Meeting.

Healio spoke with Debu Tripathy, MD, about treatments being developed for breast cancer.

Circulating tumor DNA measurements before and during treatment could help guide selection of therapy for patients with BRAF V600-mutant unresectable or metastatic melanoma, according to study results published in The Lancet Oncology.

Circulating tumor DNA analysis outperformed an established biomarker in predicting risk for colorectal cancer recurrence after surgery, according to study results presented at Gastrointestinal Cancers Symposium.